HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CFM 2

structure in first source

Also Known As:

1-(4'-aminophenyl)--3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one; CFM-2

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        Benzodiazepinones
        CFM 2: 6

Experts

1.	Ikonomidou, Chrysanthy: 2 articles (01/2018 - 12/2007)
2.	Rzeski, Wojciech: 2 articles (01/2018 - 12/2007)
3.	Sifringer, Marco: 2 articles (01/2018 - 12/2007)
4.	Stepulak, Andrzej: 2 articles (01/2018 - 12/2007)
5.	Grabarska, Aneta: 1 article (01/2018)
6.	Luksch, Hella: 1 article (01/2018)
7.	Marzahn, Jenny: 1 article (01/2018)
8.	Ruiz, Domingo Sanchez: 1 article (01/2018)
9.	Staufner, Christian: 1 article (01/2018)
10.	Temme, Achim: 1 article (01/2018)

Related Diseases

1.	Seizures (Absence Seizure) 03/05/1999 - "Thus, the administration of a challenge dose of pentylentetrazole (15 mg kg(-1) i.p.) or picrotoxin (1.5 mg kg(-1) i.p.) 15 or 30 days after the end of the repeated treatment showed that animals treated with CFM-2 were significantly protected against seizures induced by pentylentetrazole or picrotoxin. " 08/20/1999 - "In particular, CFM-2 has been proven to possess anticonvulsant activity in various models of seizures, acting as alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA) receptor antagonist." 11/01/2006 - "CFM-2 [1-(4-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one] and THIQ-10c [N-acetyl-1-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline], are two non-competitive 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic acid (AMPA) receptor antagonists, which demonstrated to antagonize generalized tonic-clonic seizures in different animal models. " 03/05/1999 - "The non-selective alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor antagonists, 2,3-benzodiazepine derivatives CFM-1 (3,5-dihydro-7,8-dimethoxy-1-phenyl-4H-2,3-benzodiazepin-4-one) and CFM-2 (1-(4'-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin -4-one), following intraperitoneal (i.p.) administration, were studied against audiogenic seizures in genetically epilepsy-prone rats (GEPRs) or pentylenetetrazole induced kindling in rats. "
2.	Neoplasms (Cancer) 01/01/2018 - "AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells." 01/01/2018 - "We show that CFM-2 inhibits survivin expression at mRNA and protein levels and decreases the viability of cancer cells. " 01/01/2018 - "Here we investigated the impact of the AMPA receptor antagonist CFM-2 on the expression of the protein survivin, which is known to promote cancer cell survival and proliferation. "
3.	Hypersensitivity (Allergy) 12/30/2008 - "Intrathecal application of two selective non-competitive AMPAR antagonists, CFM-2 (25 and 50 microg) and GYKI 52466 (50 microg), significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at 2 and 24 h post-CFA injection. "
4.	Epilepsy (Aura) 03/05/1999 - "The data suggest that, following repeated treatment, tolerance to the novel AMPA receptor antagonists does not develop (CFM-1 in genetically epilepsy-prone rats and CFM-2 in the pentylentetrazole kindling model of epilepsy). " 03/05/1999 - "The non-selective alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor antagonists, 2,3-benzodiazepine derivatives CFM-1 (3,5-dihydro-7,8-dimethoxy-1-phenyl-4H-2,3-benzodiazepin-4-one) and CFM-2 (1-(4'-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin -4-one), following intraperitoneal (i.p.) administration, were studied against audiogenic seizures in genetically epilepsy-prone rats (GEPRs) or pentylenetetrazole induced kindling in rats. "
5.	Adenocarcinoma of Lung 12/01/2007 - "Here we report that the AMPA antagonists GYKI 52466 and CFM-2 inhibit the extracellular signal regulated kinase (ERK1/2) pathway, an intracellular signaling cascade which is activated by growth factors and controls proliferation of lung adenocarcinoma cells. "

Related Drugs and Biologics

1.	AMPA Receptors (AMPA Receptor)
2.	GYKI 52466
3.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
4.	Intercellular Signaling Peptides and Proteins (Growth Factors)
5.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
6.	Messenger RNA (mRNA)
7.	Proteins (Proteins, Gene)
8.	Picrotoxin
9.	Pentylenetetrazole (Metrazol)
10.	Anticonvulsants (Antiepileptic Drugs)